Spots Global Cancer Trial Database for smoldering plasma cell myeloma
Every month we try and update this database with for smoldering plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | NCT05014646 | Smoldering Plas... | Cholestyramine Leflunomide | 18 Years - | City of Hope Medical Center | |
| Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | NCT05136807 | Monoclonal Gamm... Smoldering Plas... | Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | NCT03631043 | Smoldering Plas... | Biopsy Specimen... Lenalidomide Vaccine Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | NCT02726750 | Monoclonal Gamm... Smoldering Plas... | Biospecimen Col... Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | NCT04370483 | Smoldering Plas... | Leflunomide Quality-of-Life... | 18 Years - | City of Hope Medical Center | |
| Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma | NCT03631043 | Smoldering Plas... | Biopsy Specimen... Lenalidomide Vaccine Therapy | 18 Years - | M.D. Anderson Cancer Center | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | NCT02726750 | Monoclonal Gamm... Smoldering Plas... | Biospecimen Col... Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | NCT02603887 | Smoldering Plas... | Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
